Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey

Analysis of 2022 Health Information National Trends Survey (HINTS) showed patient -provider lung cancer screening (LCS) discussions have increased after 2021 USPSTF guideline change, but remain low with only 9.4% of potentially LCS-eligible patients discussing low -dose CT (LDCT) with their providers. Online portal use and being a current smoker were associated with higher LCS discussion. Multi -level interventions to address barriers to LCS should be implemented. Background: The US Preventative Service Task Force (USPSTF) updated lung cancer screening (LCS) recommendations with annual low -dose CT (LDCT) in 2021. We aimed to assess prevalence of patient -provider discussion about LCS and determine its associated factors. Materials and Methods: Using data from Health Information National Trends Survey (HINTS) 2022 cycle 6, 2 cohorts were evaluated: (1) potentially LCS-eligible, included participants at least 50 years old with a history of smoking and no prior history of lung cancer; (2) LCS-ineligible individuals based on age (eg, 18-49 years old), smoking history (eg, never smoked), or history of lung cancer. We assessed association of demographic, clinical, and social factors with LDCT discussion in a multivariable logistic regression model. Results: Among potentially LCS-eligible patients, 19% had never heard of LDCT and only 9.4% had discussed LCS with their provider within the past year. Those who accessed online patient portals were more likely to discuss LCS with their healthcare provider (OR, 4.25; 95% CI, 1.67, 10.81; P , .003), as were respondents with a history of current (vs. former) smoking (OR, 3.15; 95% CI, 1.21, 8.19; P , .019). Among LCS-ineligible, 1.9% discussed LCS with their providers. Individuals with a personal history of cancer (OR, 6.70; 95% CI, 1.65, 27.19; P , .009), and those who discussed colorectal cancer screening (OR, 5.74; 95% CI, 1.63, 20.14; P , .007) were more likely to discuss LCS with their provider. Conclusion: Despite updated USPSTF recommendations, rates of patient -provider LCS remains low. Multi -level interventions to address barriers to LCS are needed. Clinical Lung Cancer, Vol. 25, No. 4, e189-e195 (c) 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY -NC -ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )